MEDICAL RESEARCH BANGLADESH ( BD )

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with...

New Aspirin-Guide mobile app helps clinicians and patients make informed decisions about aspirin use Posted in:  Device / Technology News  |  Medical Research News  |  Medical Condition News  |  Pharmaceutical News Published on June 21, 2016 at 12:15 PM Low dose aspirin is recommended by clinicians as a preventive measure for patients who have already had a heart attack or stroke, but the risk of taking low-dose aspirin to prevent or delay a first heart attack or stroke is less clear, as the benefit for reducing the risk of cardiovascular disease (CVD) must be balanced with the increased risk of gastrointestinal or other bleeding. To help clinicians and patients make informed decisions about aspirin use, researchers at Brigham and Women's Hospital have developed a new, free, mobile app, "Aspirin-Guide" that calculates both the CVD risk score and the bleeding risk score for the individual patient, and helps clinicians decide which patients are approp...

Penicillin, one of the scientific marvels of the 20 th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs." Bacteria have been chipping away at the power of the penicillin family of drugs since their first wide-scale use as antibiotics in the 1940s. For example, the staph infection, brought about by the bacterium Staphylococcus aureus, was once readily treated with penicillin and its molecular cousins. But that bug has changed. In the 1960s, a new strain arrived, termed MRSA for methicillin- (or sometimes multidrug-) resistant S. aureus. It has become a serious public health problem because the earliest deployed antibiotics are often useless against the new strain, and its prevalence has only increased since it was first observed. MRSA (pronounced mer-suh) is sometimes cal...

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell dea...

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea...

Stem Cells Fill Gaps in Bones  For many patients the removal of several centimetres of bone from the lower leg following a serious injury or a tumour extraction is only the beginning of a long-lasting ordeal. Autologous stem cells have been found to accelerate and boost the healing process. Surgeons at the RUB clinic Bergmannsheil have achieved promising results: without stem cells, it takes on average 49 days for one centimetre of bone to regrow; with stem cells, that period has been reduced to 37 days. In the past, large bone defect inevitably led to an amputation. Today, the arm or leg is stabilised in an external support, and a transport wire is pulled through the marrow of the intact part of the injured bone. Once the soft tissue surrounding the injury is healed, the surgeons cut the healthy part of the bone into two. The transport wire is affixed to the winches of a ring fixator that is attached around the leg. Using a sophisticated cable-pull system, the previously d...